GlassScriptPhysician profile
Stewart Baroff
NPI 1760468086
$16,577.88
in general payments reported to CMS, 2019-2025
61 companies · $2,277 in 2025
The $2,277 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $1,700 · 2021: $3,254 · 2022: $2,777 · 2023: $2,553 · 2024: $2,699 · 2025: $2,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,523 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,522.56 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,167.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,375.97 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $1,292.22 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $881.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $740.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $736.69 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $733.90 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $732.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $729.78 | 2019-2025 | Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $568.52 | 2021-2024 | |
| Allergan, INC. | $520.33 | 2019-2021 | |
| Amgen INC. | $411.48 | 2019-2025 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $340.28 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $314.00 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $263.55 | 2022-2025 | Ingrezza |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $249.21 | 2019-2025 | Eliquis, Camzyos |
| Vanda Pharmaceuticals INC. | $239.68 | 2021-2025 | Fanapt, Hetlioz |
| Medtronic, INC. | $232.53 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $219.57 | 2021-2025 | Freestyle Libre 3 |
| Ucb, INC. | $216.25 | 2022-2024 | Nayzilam, Briviact |
| Otsuka America Pharmaceutical, INC. | $215.81 | 2023-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $189.47 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $174.19 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.35 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $136.70 | 2023-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $130.43 | 2023 | Quviviq |
| Eisai INC. | $124.54 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $120.83 | 2019-2025 | Nuplazid, Daybue |
| Sanofi-Aventis U.S. LLC | $118.70 | 2019-2023 | |
| Neurelis, INC. | $114.62 | 2024-2025 | Valtoco |
| Esperion Therapeutics, INC. | $102.85 | 2020-2024 | Nexletol |
| Mylan Specialty L.P. | $102.22 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.95 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $74.03 | 2021 | |
| Cequr Corporation | $70.68 | 2024 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $68.98 | 2022-2023 | Seglentis |
| Mannkind Corporation | $59.98 | 2019-2024 | |
| Biomerieux INC | $47.96 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Biogen, INC. | $46.22 | 2021 | |
| Merck Sharp & Dohme LLC | $37.61 | 2020 | |
| Tolmar, INC. | $34.81 | 2025 | Jatenzo |
| Lundbeck LLC | $34.50 | 2025 | Rexulti |
| Amarin Pharma, INC. | $31.75 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $30.51 | 2024-2025 | Uptravi, Opsumit |
| Biohaven Pharmaceutical Holding Company LTD. | $25.96 | 2022 | |
| Horizon Therapeutics Plc | $23.24 | 2019-2020 | |
| Circassia INC. | $23.18 | 2019 | |
| Harmony Biosciences LLC | $21.90 | 2020 | |
| Inogen, INC. | $21.51 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Boston Scientific Corporation | $21.27 | 2025 | Watchman Flx |
| Alkermes, INC. | $19.53 | 2025 | Aristada, Lybalvi |
| Cmp Pharma, INC. | $18.70 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.48 | 2019 | |
| Abiomed | $18.10 | 2023 | Impella |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.58 | 2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $17.52 | 2023 | |
| Almatica Pharma LLC | $14.98 | 2021 | |
| Aimmune Therapeutics, INC. | $14.42 | 2024 | |
| Astellas Pharma US INC | $12.86 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.26 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Baroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.